INM Fair Value & Analysis
Healthcare · PL · Market cap 38.0M PLN (≈ $10.1M)
Risks
Fair value as of: Aug 24, 2026
From 3 valuation models · updated 7 days ago
Fair value updated Aug 24, 2026, revised from 0.0100 PLN to 0.0400 PLN (+300.0%) since Jun 26, 2026. Share price +4.8% over the past month.
Below-average quality, and trading another 171% above our fair value.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The price sits above even our optimistic bull case (0.0400 PLN). The favourable scenario is already priced in.
- Weak quality (35/100) and above fair value at the same time, the margin of safety is missing on both counts.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 24, 2026.
How to read this chart
60‑month range 0.0990 PLN – 0.3325 PLN · fair‑value band 0.0300 PLN – 0.0400 PLN · the 0.1085 PLN price screens above the 0.0400 PLN fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 24, 2026.
Analysis
INM (INM) currently trades at 0.1085 PLN, while our model-based Fair Value estimate is 0.0400 PLN, implying the stock looks roughly 63.1% overvalued today. The Quality Score stands at 35/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Net debt stands at 2.7M PLN. Fundamentals as of Aug 24, 2026
Our scenario range runs from 0.0300 PLN (bear case) to 0.0400 PLN (bull case); at 0.1085 PLN, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 43% below its 52-week high and 12% above its 52-week low. For context, the median of 10 Healthcare peers we cover trades at -10% fair-value upside, at -63%, INM screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 3 models by family
Notify me when INM reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
Figures from reported company fundamentals · as of Aug 24, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 30 · Market factors (momentum, volatility) 26
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
INM reported revenue of 3.2M PLN in FY2025 versus 10.5K PLN in FY2021, a compound +317.4%/yr. Reported net income was −1.3M PLN in FY2025.
INM screens 171% overvalued. Compare with InBody Co →
Peer Group
Health Care · 2480 stocks
How this stock ranks against its sector: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median. (Industry “Healthcare Equipment & Supplies” was too small, so the broader sector is used.)
Valuation Multiples vs Health Care median · lower = cheaper
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Healthcare Equipment & Supplies stocks, each showing price versus our Fair Value estimate (as of Aug 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| InBody Co 041830 | 67,400 KRW | 49,984 KRW | -26% |
| i-SENS, Inc 099190 | 17,750 KRW | 8,168 KRW | -54% |
| Value Added Technology Co 043150 | 19,140 KRW | 60,242 KRW | +215% |
| Mediana Co 041920 | 10,070 KRW | 6,289 KRW | -38% |
| Meta Biomed Co 059210 | 3,980 KRW | 9,268 KRW | +133% |
| Sewoon Medical Co 100700 | 2,300 KRW | 6,054 KRW | +163% |
| MEKICS CO., Ltd 058110 | 1,680 KRW | 1,581 KRW | -6% |
| CU Medical Systems, Inc 115480 | 2,195 KRW | 1,134 KRW | -48% |
| PeopleBio, Inc 304840 | 561.00 KRW | 504.98 KRW | -10% |
| Eli Lilly and Company LLY | $1,176 | $389.47 | -67% |
Compare INM with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Discover undervalued stocks
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is INM overvalued or undervalued?
What is the fair value of INM?
What is the quality score of INM?
What is the net profit margin of INM?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Watch INM in the live analysis
One click puts INM on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.